https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
With billions of dollars in research and development (RD) funding continuing to be invested, the novel coronavirus disease 2019 (COVID-19) has become into a singular focus for the scientific community. However, the collective response from the scientific communities have seen poor return on investment, particularly for therapeutic research for COVID-19, revealing the existing weaknesses and inefficiencies of the clinical trial enterprise. In this article, we argue for the importance of structural changes to exist
Like
Comment
Share
